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Abstract:
Lead is the major environmental toxin
resulting in the ill health and deleterious effect
on almost all organs in the human body in a slow
and effective manner. The best treatment for
lead poisoning is chelation therapy which is
next only to prevention. The authors describe
the disruption of homeostasis of the human
body by lead in various tissues like blood,
bones, liver, kidneys and brain; and the ability
of lead to enter the cell using calcium channels
and calcium receptors like Ca++ dependant K+
ion channels, transient receptor potential
channels, T-tubules, calmodulin receptors,
inositol trisphosphate receptors and ryanodine
receptors. We report a few novel chelating
agents like ionophores, decadentate ligands,
picolinate ligands, octadentate ligand, allicin,
thiamine, that show good potential for being
used in chelation therapy. Future of lead
poisoning is a challenge to all and it needs to
be meticulously studies to have an economic
and health approach.
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Introduction:
Lead is an element that is described to be purely
toxic to all forms of life. Elements like
manganese, selenium, nickel and molybdenum,
although toxic at high levels, are actually
required nutrients at lower levels. In the case
of lead, no nutritional value or positive
biological effect has been shown at even the
lowest concentrations. Exposure to lead can
produce a wide range of adverse health effects
to all age groups. Both adults and children can
suffer from the effects of lead poisoning, but
childhood lead poisoning is much more
frequent and severe because the damage done
is irreversible. Despite an overall decrease in
human exposure to lead in recent years, the
potential for high intake of lead still exists in
millions of homes and in many occupational
places [1-5]. In India by the efforts of The
National Referral Center for Lead Poisoning
(NRCLP), there is a growing awareness of the
health threat posed by lead, which has
stimulated increased efforts to develop a
detailed characterization of the biological
behaviour of lead in humans. In order to
effectively treat lead poisoning, one must
understand the distribution of lead in different
tissues, calcium channels and calcium
receptors the lead uses to gain entry into a cell.
This review paper covers the above mentioned
aspects and some novel chelating agents that
show potential in chelation therapy for lead
poisoning.
Distribution of lead in different tissue
Lead enters the human body by inhalation,
ingestion and skin absorption [6]. On entering
the body, lead gains access to the circulatory
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system. From here, it can move into various
tissues [7]. An attempt to trace the movement
of lead in blood, bones, liver, kidneys and brain
is done in this review paper.
The total body burden of lead can be
determined only by measuring the blood lead
levels which is measured in micrograms of lead
per deciliter of blood (ìg/dl). The US Centers
for Disease Control and Prevention and the
World Health Organization state that a blood
lead level of 10 ìg/dl or above is a cause for
concern; however, lead may impair
development and have harmful health effects
even at lower levels, and there is no known safe
exposure level [8, 9]. The blood lead level is
measured using Anodic Stripping Voltammetry
(ASV) which is a sensitive and reproducible method
for analysis of trace metal ions and Graphite
Furnace Atomic Absorption Spectrometry
(GFAAS) [10,11]. The Food and Drug
Administration (FDA) has approved a portable
blood lead analyzers called Lead Care II which
is on par with GFAAS and ASV.
Blood (Fig. 1):
The pathways of lead in the blood first begin in
the blood plasma. Under steady state most of
the plasma lead is present bound to proteins with
á-globulin [12, 13]. Blood plasma is classified
into two distinct components, diffusible blood
plasma and non-diffusible blood plasma [14,
15]. There is a gradual shift of a large portion
of lead from diffusible to non-diffusible
plasma protein. Lead absorbed into blood is said
to be present in the diffusible plasma. From the
diffusible plasma, part of the lead moves into
RBCs and the other part moves into soft-
tissues via extra vascular fluid [12, 13, 16]. A
small portion of lead from diffusible plasma
also moves into the protein bound non-
diffusible plasma, which slowly returns back
lead to the diffusible plasma to be replaced at a
half-time of 5 days [16-19]. The maximum
plasma lead is present in the non-diffusible
plasma. Total plasma may contain less than 2%
of blood lead.
RBC receives one-fourth of lead form
diffusible plasma and RBC returns lead to
diffusible blood plasma at a half-time of 5 days.
[17, 19] RBC has high affinity for lead and
contains 95-99% of entire blood lead. One-
third of the lead absorbed by the body reaches
the blood in 2-3 minutes of which three-fourth
of blood lead is present in RBC [19-23]. Over
the next week, lead is lost from the RBC with a
net half-time of 15-20 days.
Fig. 1: Schematic representation of the
distribution of lead in blood
Lead moves from diffusible plasma to Extra
Vascular Fluid (EVF) which in turn moves to
the retention sites in the tissues in a time and
concentration dependant process [14,15]. This
movement of lead is treated as if it passed
directly from the diffusible plasma to the
retention sites in the tissue and therefore, in
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effect, is regarded as passing instantaneously
through the EVF [13, 16]. The EVF is three
times the size of plasma pool and therefore,
the EVF  contains three times as much lead as
diffusible plasma [18, 19].
Bone (Fig. 2):
There is a quantitatively similar behaviour
between lead and alkaline earth metals like
calcium to a great extent with regard to bone
[18]. The model of lead distribution in bone
proposed: 1) Bone is divided into four primary
parts: cortical surface, cortical volume,
trabecular surface, and trabecular volume.
2) The rapidly exchangeable material in bone
is assumed to reside on bone surfaces,
meaning endosteal and periosteal surfaces of
cortical bone, surfaces of Haversian and
Volkmann canals, surfaces of resorption
cavities, and surfaces of trabecular bone. Bone
surfaces do not include the surfaces of lacunae
or canaliculi and should not be confused with
the surfaces of the sub-microscopic bone
crystals. 3) The more slowly exchangeable
material in bone is assumed to reside in bone
volume. 4) Long term loss from bone is
associated primarily with bone resorption
which occurs under hormonal influence in
pregnant and lactating mothers [23, 24].
Cortical and trabecular bone volume are each
viewed as consisting of two pools, referred to
as the exchangeable and non-exchangeable
pools respectively. The exchangeable bone
volume pool is known to contain calcium like
substances moving from bone surface to bone
volume and are assumed to leave this pool with
an element of specific half time [25-27]. Part
of the lead leaving the exchangeable bone
volume returns to the exchangeable bone
surface and the other part enters the non-
exchangeable bone volume from which the lead
is removed to the diffusible plasma by bone
resorption [28]. Rabinowitz suggested that not
all bone lead is equally exchangeable with blood
but has varying degrees of accessibility until
penetrating the crystal surface, after which it
becomes firmly buried and must await
osteoclastic turnover [29]. The concentration
of lead is initially much higher in trabecular
than cortical bone. There is four times as much
cortical bone as trabecular bone by mass in the
skeletal system and the rate of transfer of lead
from diffusible plasma to trabecular surface is
five-fourth times higher than that in cortical
surface [25]. It is interesting to note that 20%
of lead entering bone volume is retained for a
long period of time. Around 20% of lead
leaving the exchangeable bone volume moves
to non-exchangeable bone volume and 80% of
that returns to the bone surface [28].
Fig. 2: Schematic representation of
distribution of lead in bone
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Liver (Fig. 3):
The liver is known to rapidly accumulate 10-
15% of systemic lead on absorption and loses
most of the lead within a week [30-34]. This is
a time bound activity which is important in
understanding the process of lead chelation.
Liver is viewed as consisting of 2
compartments: Liver 1 which has high lead
uptake from plasma and short half-time, Liver
2 which has low lead uptake but with high
retention time it gradually builds up lead
content over time [35,36].
Of all the lead entering the liver from the
diffusible plasma, around 4% gets deposited in
liver 1 and the removal half-time from liver 1
is 10 days. 45% of the lead from liver 1 enters
the small intestine as biliary secretions, another
45% returns to the diffusible plasma and 10%
of the lead in liver 1 is transferred to liver 2
where it is stored for a long time where the
removal half-time is about 1 year. All the lead
leaving the diffusible plasma is assumed to
return to the diffusible plasma over time. Liver
may contain 2-3% of total body lead [37, 38].
Fig. 3: Schematic representation of distri-
bution of lead in liver
Kidney (Fig. 4):
15-20% of lead from the exchangeable blood
plasma enters the kidney within 1-2 hours. A
substantial amount of the lead that enters the
kidney is excreted as urine or reabsorbed into
the blood within a few hours [39, 40].
Comparison of the decline of renal and hepatic
activity over the first two months indicates a
half-time in the kidneys that would be roughly
one-half of that in the liver [41]. The kidney is
viewed as containing two compartments,
urinary path and the other kidney tissue. The
urinary path has relatively high lead deposition
but short retention time. The other kidney
tissue has relatively low lead deposition but high
retention time.
Both these compartments receive lead from the
blood plasma. Lead in the urinary path
compartment moves to the urinary bladder.
Lead goes through glomerular filtration,
tubular absorption and tubular secretion after
which it is excreted [42]. Around 2% of plasma
lead is said to enter the urinary path
compartment and 0.02% of plasma lead enters
the other kidney tissue which has tenacious lead
retention ability. The removal half-time from
the other kidney tissue to the diffusible plasma
is about 1 year.
Fig. 4: Schematic representation of
distribution of lead in kidney
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Brain (Fig. 5):
The brain was treated as a single compartment,
but now treated as distinct compartments. This
organ is extremely sensitive to lead toxin. Lead
is distributed unevenly in the brain, which
depends on the amount of lead exposure. At low
levels, the lead concentration in different
regions of the brain is significantly correlated
with the potassium concentrations, indicating
that lead is mostly accumulated in the cell rich
parts of the brain like the hippocampus [43-45].
Lead that enters the cell gets accumulated in
the mitochondria and in calcium rich centers.
At very high concentrations of lead, there is
change in blood-brain barrier and lead enters
neuronal tissue. In young children with high lead
poisoning, sometimes the lead concentration
in the brain even exceeds that of liver and
kidneys. The brain has low lead uptake capacity,
but it has high tenacious lead retention
capacity [46]. The brain can accumulate up to
0.1% of body lead with a half-time of 2 years
for children and up to 0.15% in adults with a
half-time of 6 months.
Fig. 5: Schematic representation of
distribution of lead in brain
Lead entering a cell:
Lead shows the ability to mimic calcium and
the accumulation of lead is generally seen in
the area where calcium concentrations are high.
This lead to the discovery that lead enters a cell
through calcium channels & calcium receptors
which are found abundantly throughout the
surface of every cell in every tissue.
Ca++ dependent K+ channel:
Calcium activated potassium channels are a
family of ion channels which are activated by
voltage or intracellular Ca++ ion [47]. They are
present in all types of cells where they are
involved in a multitude of physiological
functions. They are tetrameric integral
membrane proteins forming transmembrane
aqueous pores through which K+ specifically
permeates. The most fundamental task carried
out by all K+ ion channels is to catalyze the
rapid permeation of K+ ions while rejecting
biologically abundant potential competitors like
Na+, Ca++, Mg++ [47-49]. This process is called
membrane hyperpolarization. Through these
channels Pb++ may also gain entry into a cell
where they cause disruption in normal function-
ing. These channels are essential for many
biological processes such as smooth muscle
contraction and neurotransmitter release. When
Pb++ gains entry, all these biological processes
may get affected.
Transient Receptor Potential Channels:
Transient Receptor Potential (TRP) Channels
is a group of channels present on the plasma
membrane of all types of cells. These
receptors are essential for the biological
Thuppil V. & Kaushik V.
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sensory processes like pain, hot, cold, pressure,
taste and vision. These channels are non-
selectively permeable to cations like sodium,
calcium, magnesium [50]. Transient Receptor
Potential Vanilloid (TRPV) is a family of
transient receptor channels which are
selectively permeable to calcium and
magnesium over sodium. TRPV ion channels
are tetrameric in structure and are either
homo-tetrameric or hetero-tetrameric [49-51].
Pb++ ions also gain entry into a cell through the
TRP receptors which then accumulate in the
mitochondria and other cell organelles to
hamper the biological functioning of the cell
and eventually cause cell death.
T-tubules:
These are deep invaginations of the sarcolemma
which is the plasma membrane in the skeletal
and cardiac tissue cells. They allow
propagation of action potential to the cell
interior allowing spatially and temporally
synchronous Ca++ release throughout the cell.
T-tubules are not simple invaginations; many of
the key proteins involved in excitation-
contraction coupling are located predominantly
at the t-tubules, which suggests that they play a
specialized and important role in Ca++ handling
and excitation-contraction coupling [52]. The
sarcolemma invaginates perpendicular to the
length of the muscle and skeletal fiber to form
what is called a T-tubule. At these invaginations,
the sarcolemma is studded with a large number
of calcium channels. It is physiologically
important for excitation-contraction coupling
that the T-tubules are positioned close to the
terminal cisternae of the sarcoplasmic
reticulum as the triad or diad arrangement
(T-tubule association with cisterne) allows
physical and functional contact by voltage
dependent calcium channels. So, an action
potential along the sarcolemma causes calcium
channels to open in the terminal cisternae/
sarcoplasmic reticulum which enables calcium
to move from the sarcoplasmic reticulum into
the cytoplasm and the intracellular calcium
concentration to increase. Lead ion gains entry
onto the cell through the same calcium
channels that the calcium ion uses.
T-tubules are the major sites for the coupling
of excitation and contraction, which is the
process whereby the spreading depolarization
is converted into force production by muscle
fibers. The calcium channels in the T-tubules
activate in response to the electrical stimulation;
their opening allows calcium to flow down its
electrochemical gradient and into the cell.
Activation of the channel also causes a
mechanical interaction between it and calcium-
release channels located on the adjacent
sarcoplasmic reticulum membrane. In skeletal
muscle, the influx of calcium through the
calcium channel on the T-tubule contributes
little to excitation-contraction coupling,
whereas it is crucial to the proper function of
cardiac muscle. Conversely, the mechanical
interaction between the T-tubules calcium
channel and the calcium-release channel is
critical to proper skeletal muscle contraction,
whereas it contributes little to the contraction
of cardiac muscle [53, 54].
Calmodulin Receptors:
Calmodulin (CaM) is a ubiquitous calcium
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binding protein expressed in eukaryotic cells.
These can bind to and regulate a multitude of
different protein targets, thereby affecting
many different cellular functions such as
inflammation, metabolism, apoptosis, muscle
contraction, intracellular movement,
short-term and long-term memory, nerve
growth and the immune response. Many of the
proteins that CaM binds are unable to bind
calcium themselves, and as such use CaM as a
calcium sensor and signal transducer. CaM can
also make use of the calcium stores in the
endoplasmic reticulum, and the sarcoplasmic
reticulum [55-57]. CaM undergoes a
conformational change upon binding to
calcium, which enables it to bind to specific
proteins for a specific response. CaM can bind
up to four calcium ions, and can undergo
post-translational modifications, such as
phosphorylation, acetylation, methylation and
proteolytic cleavage, each of which can
potentially modulate its actions [57]. Increased
calcium concentrations lead to calcium
binding by regulatory proteins, which can turn
the calcium signal into a biological response.
There are many such regulatory proteins that
bind calcium, which together form an intricate
network of feedback loops to control the
location, amount and effect of calcium influx.
Calmodulin is one such calcium-binding
protein that is considered a major transducer
of calcium signals [55-57]. If lead binds to
calmodulin instead of calcium, then all the
above mentioned vital biological process are
hampered.
Inositol Trisphosphate Receptor:
Inositol trisphosphate receptor (InsP3) is
involved in the regulation of numerous
processes, including transepithelial transport,
learning and memory, muscle contraction,
membrane trafficking, synaptic transmission,
secretion, motility, membrane excitability, gene
expression, cell division, and apoptosis. It
involves the activation of phospholipase C. This
phospholipase C hydrolyzes the membrane lipid
phosphatidylinositol 4, 5-bisphosphate,
generating inositol 1, 4, 5-trisphosphate
(InsP3). InsP3 diffuses in the cytoplasm and
binds to its receptor (InsP3R), which is an
intracellular ligand-gated Ca++ release channel
localized primarily in the endoplasmic
reticulum (ER) membrane. The ER is the
major Ca++ storage organelle in most cells [58].
Upon binding InsP3, the InsP3R is gated open,
providing a pathway for Ca++ to diffuse down
this electrochemical gradient from the ER
lumen to cytoplasm [59]. Pb++ when present in
the medium can also diffuse down this electro-
chemical gradient and enter the cytoplasm. The
distribution and concentrations of Ca++
binding proteins and the release channels, as
well as the complex properties of the release
channels, enable InsP3R-mediated Ca++ ion
signals to have diverse spatial and temporal
properties that can be exploited by cells,
making this signaling system remarkably robust.
Consequently, despite its expression in
probably all cells in the body, this signaling
system can provide specific signals that
regulate diverse cell physiological processes
[58-60].
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Ryanodine Receptor:
These are a class of intracellular calcium
channels seen in muscles and neurons.
Ryanodine Receptor (RyR) corresponds to the
Sarcoplasmic Reticulum (SR) Ca++ channel, but
also seen on other organelles. The channel in
the RyR is a cation-selective channel with low
cation selectivity with Ca++ having high
permeability, but, Pb++ ions can use the same
calcium ion channel [61]. The RyR mediates the
efflux of Ca++ from the SR or other intracellular
stores. It has a central role in excitation-
contraction coupling between sarcolemmal
depolarization and SR Ca++ release. The
sarcolemmal depolarization produces a
conformational change in the dihydropyridine
receptor that is transmitted to the RyR and this
induces the release of Ca++ from the SR.
Alternatively, excitation-contraction coupling
might be mediated by a process known as Ca++
induced Ca++ release. As the SR channel is
activated by an increase in cyosolic Ca++ ions,
the sarcolemmal Ca++ current could induce
further release of Ca++ from the SR. This
process may be favoured by the existence of
Ca++ gradients in the cytosol, because Ca++ ions
entering the cell through the dihydropyridine
receptor seem to have preferential access to
the RyR [61, 62].
Chelating agents:
Chelating agents are divided into Prophylactic
chelators and Therapeutic chelators.
Prophylactic chelators are mainly used as a
preventive treatment using natural chelating
agents to avoid lead poisoning. Therapeutic
chelating agents are used as treatment using
synthetic chelating agents or derivatives of
natural chelating agents which are used after the
conformation of the diagnosis of lead
poisoning. There is continuous development in
the field of chelation therapy; therefore there
is a constant change in the dosage and mode of
administration of these chelating agents. For
example, administration of CaNa2EDTA as
rectal suppositories has been successful in
decreasing lead concentration in the brain and
prostrate [63]. Prophylactic chelators are
mostly naturally available, garlic, cloves and
cilantro leaves consumed raw, chlorella, single
celled green algae is also known to reduce lead
content in the body [64,65,66]. Vitamin C, tea
and Indian gooseberry mainly act as antioxidants
which help in combating the reactive oxygen
species generated due to lead poisoning [67,
68, 69]
New chelating agents:
Today the best treatment for lead poisoning is
chelation therapy. Over the years many
chelating agents have been used successfully
to treat lead poisoning. For example,
CaNa2EDTA, Succimer (meso-DMSA)
Dimercaprol (BAL), Unithiol (DMPS),
D- penicillamine (DPA) and many more. In this
review paper, we cover the new and emerging
lead chelating agents, most of which are still
under study. These show good potential to be
used in chelation therapy to treat lead poisoning.
Ionophores:
Chelating agents bind to plasma lead but
cannot cross the cell membranes where the
total body lead burden lies. Some ionophores
have been shown to transport lead across the
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cell membrane providing a novel method for
reducing body burden of lead [70,71]. Pyrithione
(N-hydroxypyridine-2-thione), a zinc
ionophore along with some 8-hydroxyquinoline
derivatives has been found to reduce lead
content in erythrocytes. Water soluble Sodium
pyrithione was found to reduce lead in whole
blood without partitioning into the erythrocytes
[71]. Monensin, a sodium ionophore is found
to be selective in transporting Pb (II) into model
phospholipid bilayer vesicles, while it does not
transport other divalent cations. Administration
of monensin, in combination with the chelating
agent DMSA, produce reduced lead levels in
liver, kidney, brain, femur, heart, and skeletal
muscle. This occurrs while the levels of
endogenous metals such as Ca(II), Mg(II), and
Zn(II) were relatively unchanged. Salinomycin,
and Lasalocid are other ionophores. They have
also shown to reduce body lead burden.
Ionophores may prove useful in mobilizing lead
into the extra cellular spaces, thereby
improving the efficiency of chelation therapy
using DMSA [72].
Macrocyclic decadentate ligands:
Chelation of heavy-metals using macrocyclic
decadentate N,N-Bis[(6-carboxy-2-pyridil)
methyl]-1,13-diaza-18 crown 6. This ligand is
found to be highly suited for the complexation
of large metal ions like Pb (II) and Sr (II) in
aqueous solution. This results in very high Pb
(II) /Ca (II) and Pb (II) / Zn(II) selectivity and
the highest Sr (II) / Ca(II) selectivity reported
so far. The Pb(II) ion is endocyclically
coordinated, being directly bound to the 10
donor atoms of the ligand. The structure of the
complex observed is the so-called hemidirected
compound, in which the Pb(II) lone pair is
stereochemically active. It shows promise for
application in chelation treatment of metal
intoxication by Pb(II) and Sr(II) [73].
Picolinate ligand:
Picolinate ligand designed to accommodate the
Pb(II) ion  pair leading to high stability and
selectivity. The crystal structure of the lead
complexes of the diprotonated and
monoprotonated tripodal ligand coordinate the
lead in an asymmetrical way leaving a gap in
the coordination sphere to accommodate the
lead lone pair. The geometry of the dipodal
ligand is designed to accommodate the lead
lone pair in the structure of the complex. The
donor atoms of the ligand occupy only a
quarter of the coordination sphere, reducing the
sterical interaction between the lead lone pair
with respect to the tripodal complexes. As a
result, in the lead structures of dipodal
complexes all the ligand donor atoms are
strongly bound to the metal ion leading to
increased stability. A remarkable increase in the
Pb/Ca selectivity is observed for dipodal ligand
compared to tripodal ligand, making the dipodal
ligand a good candidate for application as lead
chelating agent [74].
Octadentate ligands:
Chelation of heavy-metals using octadentate
ligands containing pyridine carboxylate and
pyridil pendants. The coordination properties
toward Cd(II), Pb(II), Ca(II), and Zn(II) of a new
octadentate ligand (py-H2bcpe) based on a
ethane-1,2-diamine unit containing two
picolinate and two pyridyl pendants. This ligand
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shows good Pb(II)/Ca(II) and Cd(II)/Ca(II)
selectivities., which increases complexation
with the heavy metal. This ligand can be
considered as a new structural framework for
the design of novel Cd(II) and Pb(II) extracting
agents. The stabilities of the Cd(II) and Pb(II)
complexes are higher than those of the
corresponding EDTA analogues. The Zn(II)
complex is six-coordinated, while the Pb(II)
complexes are eight-coordinated [75].
Allicin:
Allicin [2-Propene-1-sulfinothioic acid S-2-
propenyl ester] is an active compound present
in Garlic which reduces lead toxicity in the body
[76]. The high permeability of the compound
enhances intercellular interactions. It does not
induce leakage, fusion or aggregation of
membrane. Crude garlic (Allium sativum)
extracts contain antioxidants that combat
against the Reactive Oxygen Species (ROS)
generated because of lead. The antioxidant
activity of garlic is attributed to biologically
active lipophilic sulfur-bearing compounds
such as allicin, S-allyl-cysteine (SAC),
diallyl-di-sulphde (DADS), and diallyl-sulphde
(DAS) and these compounds can easily
permeate through phospholipid membranes and
reduce intracellular lead [64,77,78]. Allicin
treatment reduced lead retention in both blood
and tissues. It is known to reduce blood, liver,
kidney, bone and ovary lead considerably. The
reduction of lead concentration in blood and
tissues is dose dependant. There are also
reports of reduced zinc concentration in the liver.
Garlic extracts also have anticarcinogenic,
hypolipidemic, hypoglycemic, antiathero-
sclerotic, antibacterial and antifungal
properties [79].
Thiamine:
Thiamine considerably reduces ovary lead
content. Lead interacts with the pyrimidine ring
of thiamine, leading to its solubilization and
thereby prevention of its accumulation and
clearance form tissues at physiological pH. The
mechanism by which this occurs is speculated
to be lead chelation. However, the exact nature
of the interaction is not very clear [80]. A
combination treatment of Thiamine and
Ascorbic acid (Vitamin C) has been effective
in reducing lead induced inhibition of delta
amino leavilinic acid dehydratase in blood and
also effective in inhibition of uptake of lead by
kidneys, liver and blood. The order of
effectiveness is Thiamine > Ascorbic acid >
Thiamine + Ascorbic acid. However, the ALAD
levels in blood show improvement in the
presence of Ascorbic acid [81]. Thiamine is also
known to reduce lead content form blood,
kidney and bone. Interestingly, thiamine appears
to prevent accumulation of lead in bone during
treatment [67]. Thiamine also increases urinary
excretion of lead.
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Table-1: Therapeutic chelating agents used to treat lead poisoning
Chelating
 Agent
Dimercaprol
(BAL)
Dimercapto-
succinic acid
(DMSA)
Dimercapto-
propane sul-
fonate (DMPS)
D-Penicillamine
Ethylenediamine
tetraacetic acid
(calcium diso-
dium versante)
(CaNa2-EDTA)
Minimum blood
Lead levels(µg/
dL) required for
usage of drug
50  60
45-60
45-55
50-60
25 - 45
Dosage
4mg/ kg. Every
4 hours for 48
hours. Then ev-
ery 6 hours for
48 hours. Then
every 6  12
hours for 7 days
[82, 83].
10mg/kg every
8hours for 5
days. Then ev-
ery 12 hours for
2 weeks [85,
86].
10 - 30 mg/kg
BW per day, ad-
ministered as 6
to 8 individual
doses of 3-5 mg/
kg, every 3-4
hours [87]
2030 mg/kg
daily [83]
25  75mg/ kg/
day Should not
exceed a total
dose of 500 mg/
kg [89-91]
Duration
11 Days
19 Days
Treatment is
continued until
the heavy metal
concentrations
in the blood and
urine are below
the limit values
[87]
Till heavy metal
concentrations
are below the
limit values
[83,88,89]
5 Days [89-91]
Mode of
application
Intramuscular
injection
[82,83].
Orally [86]
Intravenous
[87]
Orally [88,89]
Intramuscular
injection, intra-
venous infusion,
oral or rectal
suppositories
[63, 89-91]
Contraindications
Instances of hepatic and
renal insufficiency with
the exception of post ar-
senical jaundice. Known
hypersensitivity to pea-
nuts [84].
Not given to patients
with advanced hepatic or
renal failure. Hypersen-
sitivity to the drug [85]
Not used in the presence
of hypersensitivity to
DMPS or its salts. Spe-
cial care is required on
injection of DMPS in
patients with allergic
asthma symptoms [87]
Not administered during
Pregnancy, lactation,
Caution is advised if
there is a prior evidence
of Cystinuria, Wilsons
disease, Lupus erythe-
matosus, Thrombocy-
topenia, agranulocytosis
[83,88,89]
Anuria, Active renal dis-
ease, Hepatitis [91]
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N-Acetyl-L-
Cysteine (NAC)
45 - 50 600-1500  mg
daily in 3 divided
doses. How-
ever, doses of
70-140 mg/kg
per day may be
used to treat ac-
etaminophen
poisoning [92].
No limit as it is
also an amino
acid supplement
Orally [92] Not administered to
patients with organ
transplant. Caution is
advised in presence of
stomach ulcers [92]
Conclusion:
The growing population and rapidly changing
environmental conditions result in the higher
usage of lead in various sectors and the
possible exposure to living organisms results
in growing environmental pollution. The usage
of lead in day to day life has increased and the
existing high concentrations of lead in the
environment are gaining entry into the human
system through various means. As awareness
about lead and its harmful effects is so less
among people, the symptoms of lead poisoning
are misunderstood and misdiagnosed and
misinterpreted. Some of the traditional
medications of different cultures have been
found to contain lead. This is a cause of worry
as most people in the rural and some people in
the urban areas are still dependant on the
traditional folk medications. It is our
responsibility as researchers to educate the
general population and health care provides on
this life threatening issue and take some
important steps for the betterment of society.
This sense of responsibility has led a lot of
researchers to explore the new horizons in
search of effective chelating agents to combat
lead poisoning. This has led to the discovery
and development of so many new lead
chelating agents, some of which have been
documented in this review paper. When
awareness is not taken seriously and
prevention fails, specific and targeted chelation
is required. This is the future of chelation
therapy where small, specific and targeted
medications are required which will be a faster
and safer means of chelation. Is it possible to
develop drugs which act  as carriers to deliver
chelating agents to specific organs and act in a
way where there is no re-distribution of the
chelated lead to other organs!
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